Key Laboratory of Structure-Based Drugs Design and Discovery (Ministry of Education), School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China.
Key Laboratory of Structure-Based Drugs Design and Discovery (Ministry of Education), School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China.
Bioorg Med Chem Lett. 2021 Dec 1;53:128420. doi: 10.1016/j.bmcl.2021.128420. Epub 2021 Oct 30.
In this paper, a new class of novel sulfonamides incorporating aminosaccharide tails were designed and synthesized based on the sugar-tail approach. Then, all the novel compounds were evaluated for their inhibitory activities against three carbonic anhydrase (CA, EC 4.2.1.1) isoenzymes (hCA I, hCA II and hCA IX). Interestingly, effective inhibition of these three CA isoforms were observed, especially the glaucoma associated isoform hCA II. It is worth noting that these glycoconjugated sulfonamide derivatives also showed better CA inhibitory effects compared to the initial segment carzenide. Among them, compound 8d was the most effective inhibitor with IC of 60 nM against hCA II. Subsequent physicochemical properties studies showed that all compounds have good water solubility and neutral pH values in solutions. And these important physicochemical properties make target compounds acquire obvious advantages in the preparation of topical and nonirritating antiglaucoma drugs. Moreover, the target compounds showed lower corneal cytotoxicity than acetazolamide (AAZ) and good metabolic stability in vitro. In addition, molecular docking studies confirmed the interactions between aminosaccharide fragment and hydrophilic subpocket of hCA II active site were crucial for the enhanced CA inhibitory activity. Taken together, these results suggested 8d would be a promising lead compound for the development of topical antiglaucoma CAIs.
在本文中,我们基于糖尾巴方法设计并合成了一类新型磺酰胺类化合物,这些化合物引入了氨基糖尾巴。然后,我们评估了所有新化合物对三种碳酸酐酶(CA,EC 4.2.1.1)同工酶(hCA I、hCA II 和 hCA IX)的抑制活性。有趣的是,这些化合物对这三种 CA 同工酶均表现出有效的抑制作用,尤其是与青光眼相关的 hCA II。值得注意的是,与最初的 carzenide 相比,这些糖基化磺酰胺衍生物也表现出更好的 CA 抑制效果。其中,化合物 8d 对 hCA II 的抑制活性最强,IC 为 60 nM。随后的理化性质研究表明,所有化合物在溶液中均具有良好的水溶性和中性 pH 值。这些重要的理化性质使目标化合物在制备局部和非刺激性抗青光眼药物方面具有明显优势。此外,目标化合物的角膜细胞毒性低于乙酰唑胺(AAZ),并且在体外具有良好的代谢稳定性。此外,分子对接研究证实了氨基糖片段与 hCA II 活性位点亲水性亚口袋之间的相互作用对于增强 CA 抑制活性至关重要。综上所述,这些结果表明 8d 可能是开发局部抗青光眼 CAIs 的有前途的先导化合物。